Monoclonal antibodies in therapy of solid tumors

Abstract

Monoclonal antibodies have become increasingly used therapeutic agents for the treatment of solid cancer. Many are now being tested as components of adjuvant or first-line therapies to assess their efficacy in improving or prolonging survival. Selected unconjugated antibodies can exert clinically significant antitumor effects in many cancers. Antibody conjugates have been used to deliver toxic principles, such as radioactive particles, chemotherapeutic agents, and catalytic toxins, with increasing success in clinical trials.